Infectious Diseases (all articles)
Brief review and algorithm | Management of latent tuberculosis infection
23 Jan, 2023 | 13:35h | UTCManagement of Latent Tuberculosis Infection – JAMA (free for a limited period)
Guideline | Diagnosis and treatment of pleural effusion
20 Jan, 2023 | 14:55h | UTCRelated:
Update on Management of Pleural Disease – Current Pulmonology Reports
Pleural Effusion in Adults—Etiology, Diagnosis, and Treatment – Deutsches Ärzteblatt international
Evaluation of the patient with pleural effusion – Canadian Medical Association Journal
State-of-the-art: Radiological investigation of pleural disease – Respiratory Medicine
Recommendations for the diagnosis and management of COVID-19 associated bacterial and fungal infections
20 Jan, 2023 | 14:48h | UTC
Use of wastewater for Mpox outbreak surveillance in California
19 Jan, 2023 | 14:24h | UTCUse of Wastewater for Mpox Outbreak Surveillance in California – New England Journal of Medicine
Related:
Opinion: Wastewater analysis can be a powerful public health tool—if it’s done sensibly.
CDC unveils its latest weapon in Covid-19 detection: wastewater.
[Preprint] Wastewater genomic testing can effectively track COVID-19 variants of concern.
Human Waste Could Be The Next Big Weapon in Controlling COVID-19 – TIME
Next steps for wastewater testing to help end this pandemic — and prevent the next one – STAT
The myriad ways sewage surveillance is helping fight COVID around the world – Nature
It’s time to begin a national wastewater testing program for Covid-19 – STAT
Coronavirus: Testing sewage an ‘easy win’ – BBC
Commentary on Twitter
In this report, the use of wastewater to conduct surveillance for the presence and spread of mpox in California is described. https://t.co/PJm8fwekxr pic.twitter.com/klzC0mbC0w
— NEJM (@NEJM) January 18, 2023
Study shows low diagnostic sensitivities of SARS-CoV-2 rapid antigen self-tests in asymptomatic individuals in the omicron period
19 Jan, 2023 | 14:23h | UTCCommentary: Study: COVID-19 rapid home tests not highly sensitive for Omicron – CIDRAP
Cohort Study | Analysis of Rituximab use and COVID-19 hospitalization or death in patients with multiple sclerosis
19 Jan, 2023 | 14:22h | UTC
Commentary on Twitter
Patients with MS on rituximab vaccinated for #COVID19 6 months before or after their last infusion had a much lower risk of COVID hospitalization – 1.4 vs 3.6 per 100 among unvaccinated people. https://t.co/am6hdSidMT
— JAMA Network Open (@JAMANetworkOpen) December 28, 2022
RCT | Aqueous povidone-iodine vs. normal saline for intraoperative wound irrigation on the incidence of SSI after GI surgery
19 Jan, 2023 | 13:54h | UTCAqueous Povidone-Iodine Versus Normal Saline For Intraoperative Wound Irrigation On The Incidence Of Surgical Site Infection In Clean-Contaminated Wounds After Gastroenterological Surgery: A Single Institute, Prospective, Blinded-Endpoint, Randomized Controlled Trial – Annals of Surgery (link to abstract – $ for full-text)
Review | Surgical site infection prevention
18 Jan, 2023 | 14:31h | UTCSurgical Site Infection Prevention: A Review – JAMA (free for a limited period)
Author interview: Surgical Site Infection Prevention – JAMA
Related:
Global guidelines on the prevention of surgical site infection – World Health Organization
AAOS Guideline: Prevention of surgical site infections after major extremity trauma.
Report | The COVID-19 pandemic and the future of telemedicine
18 Jan, 2023 | 14:28h | UTCNews Release: New report looks to the future of telemedicine – Imperial College London
M-A | Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection
18 Jan, 2023 | 14:27h | UTCNews Release: COVID-19 infection at any time during pregnancy boosts mother’s risk of death – BMJ
Commentary: Getting COVID in Pregnancy Greatly Raises a Woman’s Odds for Death – HealthDay
Consensus statement | Use of a 4-month treatment regimen for drug susceptible TB in children with uncomplicated disease
18 Jan, 2023 | 14:25h | UTC
SR | Pre‐emptive antifungal therapy vs. empirical antifungal therapy for febrile neutropenia in people with cancer
18 Jan, 2023 | 14:18h | UTC
M-A | Increased risk of acute myocardial infarction after COVID-19 recovery
17 Jan, 2023 | 13:22h | UTC
Impact of SARS-CoV-2 variants on inpatient clinical outcome
17 Jan, 2023 | 13:21h | UTCImpact of SARS-CoV-2 variants on inpatient clinical outcome – Clinical Infectious Diseases
SHEA statement on antibiotic stewardship in hospitals during public health emergencies
17 Jan, 2023 | 13:18h | UTC
Review | Viral infections in critical care
17 Jan, 2023 | 13:01h | UTCViral infections in critical care: a narrative review – Anaesthesia
M-A | Colonisation with ESCR-Enterobacterales and infection risk in surgical patients
17 Jan, 2023 | 12:58h | UTC
WHO updates COVID-19 guidelines on masks, treatments and patient care
15 Jan, 2023 | 20:44h | UTCWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
WHO Updated Guidelines:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Review | Long COVID: major findings, mechanisms and recommendations
15 Jan, 2023 | 20:34h | UTCLong COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
15 Jan, 2023 | 20:33h | UTCA survey of COVID-19 vaccine acceptance across 23 countries in 2022 – Nature Medicine
News Release: Global COVID-19 vaccine acceptance rising but hesitancy remains – London School of Hygiene & Tropical Medicine
Commentary on Twitter
The third annual iteration of a survey assessing vaccine confidence in 23 countries shows the overall willingness to accept a COVID-19 vaccine has increased, although results were heteregeous across countries, according to a @NatureMedicine paper. https://t.co/0EkMH7oRdn pic.twitter.com/bLc98F9AYt
— Nature Portfolio (@NaturePortfolio) January 13, 2023
RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19
15 Jan, 2023 | 20:37h | UTCEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Commentary on Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Best infectious diseases articles from 2022 – A year end review of non-COVID literature
15 Jan, 2023 | 20:31h | UTC
Commentary on Twitter
🔥🔥NEW 🔥🔥
Our new post, a great collaboration w 🌟 @IDstewardship
Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
1️⃣7️⃣⚡️🆔 RCTs @NEJM @TheLancet ✨
2️⃣syst Rev
3️⃣🌏Guidelines @Wiki_Guidelines
#IDTwitter #TwitteRxhttps://t.co/JL07NLa3BV pic.twitter.com/Qcf2cwK8Sd— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) January 4, 2023
Retrospective Study | Most patients with long Covid developed after mild infection get better within a year
13 Jan, 2023 | 13:42h | UTCLong covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study – The BMJ
News Release: Most long COVID effects resolve within a year after mild infection, finds study- British Medical Journal
Commentary: Long COVID After Mild Infection? It Fades Within a Year – HealthDay
Study identified six clusters of patients with long COVID, with distinct profiles of phenotypic abnormalities
13 Jan, 2023 | 13:40h | UTCGeneralisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes – eBioMedicine
RCT | Colistin monotherapy vs. combination therapy for carbapenem-resistant organisms
13 Jan, 2023 | 13:36h | UTCColistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms – NEJM Evidence
Commentary: Colistin Alone or with Meropenem: Is More Better? – NEJM Journal Watch